Sector News

Alexion to create 200 jobs in Dublin expansion

May 12, 2015
Life sciences
Biopharma group Alexion has announced plans for a major expansion of its Irish business.
Alexion, which is still building the first page of its planned Dublin base, said it will invest a further € 450 million to extend the facility over the next four years.
The expansion will see the US-based specialist in rare and ultra rare diseases construct its first biological manufacturing facility outside the US.
The company makes Soliris, one of the world’s most expensive drugs, which is used to treat two rare blood conditions.
The drug, which costs in the region of € 430,000 per patient per year, received approval for use in Ireland earlier this year after a protracted negotiation.
Alexion expects to create 200 jobs with the investment, nearly doubling the numbers employed in Ireland by the company since its arrival here in 2013.
Alexion’s Irish executive VP for global operations Julie O’Neill said the project “further underscores our commitment to Ireland and is enabled by our ability to recruit highly competent and professional personnel”.
Tanaiste Joan Burton welcomed the announcement and said the company brought the “miracle of hope to parents of children who have life limiting and life threatening conditions”.
Also speaking at the announcement, Minister for Enterprise Richard Bruton characterised Alexion as a “wonderful company” whose founders “have fantastic passion”.
By Dominic Coyle
Source: Irish Times

Related News

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]

September 16, 2020

Takeda unveils new Boston R&D manufacturing center for cell therapy pipeline push

Life sciences

Japanese drugmaker Takeda has trumpeted its plan in recent years to cut billions of dollars in costs and pivot around oncology and rare diseases. A key part of that strategy […]

September 15, 2020

AstraZeneca, Oxford restart stalled COVID-19 test as Pfizer ramps up trial numbers for its vaccine

Life sciences

Just under a week after it stopped its key phase 3 pandemic vaccine test, AstraZeneca and the University of Oxford have been given the green light to restart in the […]